Development of cardiomyopathy and atrial tachyarrhythmias associated with activating autoantibodies to beta-adrenergic and muscarinic receptors.
A 71-year-old male with well-controlled hypertension developed atrial tachyarrhythmias in 2002 and a restrictive cardiomyopathy in 2006 to 2007. Sera from 1992, 2001, and 2006 to 2008 demonstrated activating autoantibodies against beta-adrenergic (AAbetaAR) and M2 muscarinic receptors (AAM2R). These sera have been characterized for bioactivity using in vitro assays of cardiac contractility and automaticity using a canine cardiac Purkinje fiber assay as well as protein kinase assay activation in H9c2 cells. These assays demonstrated concurrent positive betaAR and inhibitory M2R effects that were blocked by nadolol and atropine, respectively. In a canine pulmonary vein atrial sleeve preparation, sera diluted 1:100 produced atrial hyperpolarization that was blocked by atropine. Atrial tachyarrhythmias developed in 2002 in the presence of a persistent bradycardia. Serial echocardiograms demonstrated progressive diastolic dysfunction in the absence of cardiac hypertrophy between 2006 and 2007. A dual-chamber pacemaker was installed with combined betaAR (nadolol) and M2<3R (oxybutynin) blockade, resulting in marked suppression of atrial ectopy and improved diastolic function. The estimated pulmonary artery pressure decreased and exercise tolerance returned. Blood pressure has remained normal with beta-blockade. AAbetaAR and AAM2R prospectively influenced atrial and ventricular function in this patient, and specific receptor blockade was associated with improved cardiac function.
Yu
Xichun
X
Heart Rhythm Institute, University of Oklahoma Health Sciences Center and VA Medical Center, Oklahoma City, Oklahoma, USA; Endocrinology, Department of Medicine, University of Oklahoma Health Sciences Center and VA Medical Center, Oklahoma City, Oklahoma, USA.
Patterson
Eugene
E
Stavrakis
Stavros
S
Huang
Shijun
S
De Aos
Isabel
I
Hamlett
Sean
S
Cunningham
Madeleine W
MW
Lazarra
Ralph
R
Kem
David C
DC
J Immunol. 2006 Dec 1;177(11):8234-40
17114501
Circ Res. 1989 Jan;64(1):97-103
2535798
Pharmacol Rev. 1999 Dec;51(4):651-90
10581327
J Mol Cell Cardiol. 2007 May;42(5):1001-7
17362986
Eur Heart J. 2004 Jul;25(13):1108-15
15231368
J Mol Cell Cardiol. 1997 Oct;29(10):2735-46
9344768
J Cardiovasc Electrophysiol. 1994 Apr;5(4):367-75
8019712
J Mol Cell Cardiol. 2004 Jul;37(1):11-21
15242731
Circulation. 1994 Jun;89(6):2760-7
8205690
Basic Res Cardiol. 2001 Nov;96(6):528-38
11770070
N Engl J Med. 2003 Oct 16;349(16):1526-33
14561795
J Cardiovasc Electrophysiol. 2002 Jan;13(1):83-7
11843490
J Am Soc Hypertens. 2008 Jan-Feb;2(1):8-14
20409879
J Clin Invest. 2004 May;113(10):1419-29
15146239
J Clin Invest. 2000 Jul;106(2):217-24
10903337
J Am Coll Cardiol. 2007 Jul 31;50(5):423-31
17662395
Clin Exp Immunol. 2006 Feb;143(2):209-15
16412044
Heart Rhythm. 2006 Oct;3(10):1182-6
17018348
Autoimmunity. 2000 Dec;32(4):271-80
11191286
Hypertension. 2007 Nov;50(5):829-34
17923587
J Cardiovasc Electrophysiol. 2007 Sep;18(10):1067-75
17655663